Progress in neuromuscular disease does not happen in isolation. It happens when the right people are in the same room, working through the same problems at the same time. That is what defines the annual MDA Clinical and Scientific Conference.
Each year, this meeting brings together clinicians, researchers, allied health providers, industry leaders, and key community leaders. They are not just presenting findings, but actively pressure-testing what comes next. The value is in what is shared, and even more importantly, in what is clarified, challenged, and accelerated over the course of a few days.
For attendees, the benefit is immediate and practical. Clinicians and allied health professionals gain insight they can apply to patient care now, translating emerging science into coordinated, day-to-day care that people and families experience directly. Researchers sharpen their work through direct exchange with peers and partners. Industry leaders engage with the realities of clinical implementation. And early-career professionals step into the full complexity of the field, not as observers, but as contributors.
For professionals in the broader research and regulatory communities, the impact runs even deeper. This conference serves as a real-time convergence point where scientific discovery, clinical application, and regulatory thinking align. Conversations that begin here influence trial design, inform regulatory pathways, and surface the barriers that we must address to move therapies forward. It is one of the few environments where these perspectives meet with urgency and candor.
That combination matters. It shortens the distance between discovery and delivery and ensures that innovation is grounded in the lived realities of people with neuromuscular disease. Finally, it reinforces a shared responsibility across sectors to move faster, together.
The MDA Clinical and Scientific Conference continues to set that pace—not by convening a community, but by activating it.
We look forward to welcoming you in 2027.
Sincerely,
Sharon Hesterlee, PhD
President and CEO
Muscular Dystrophy Association